These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38227621)

  • 1. Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.
    McElroy SL; Guerdjikova AI; Blom TJ; Mori N; Romo-Nava F
    J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):89-95. PubMed ID: 38227621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
    Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
    JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
    White MA; Grilo CM
    J Clin Psychiatry; 2013 Apr; 74(4):400-6. PubMed ID: 23656848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.
    Whicher CA; Price HC; Phiri P; Rathod S; Barnard-Kelly K; Reidy C; Thorne K; Asher C; Peveler R; McCarthy J; Holt RIG
    Trials; 2019 Nov; 20(1):633. PubMed ID: 31747930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
    Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
    Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing cognitive behavioural therapy for eating disorders integrated with behavioural weight loss therapy to cognitive behavioural therapy-enhanced alone in overweight or obese people with bulimia nervosa or binge eating disorder: study protocol for a randomised controlled trial.
    Palavras MA; Hay P; Touyz S; Sainsbury A; da Luz F; Swinbourne J; Estella NM; Claudino A
    Trials; 2015 Dec; 16():578. PubMed ID: 26683478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
    O'Neil PM; Garvey WT; Gonzalez-Campoy JM; Mora P; Ortiz RV; Guerrero G; Claudius B; Pi-Sunyer X;
    Endocr Pract; 2016 Nov; 22(11):1277-1287. PubMed ID: 27482610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.
    Pandey A; Patel KV; Segar MW; Ayers C; Linge J; Leinhard OD; Anker SD; Butler J; Verma S; Joshi PH; Neeland IJ
    J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1072-1083. PubMed ID: 38561962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
    Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.
    Whicher CA; Price HC; Phiri P; Rathod S; Barnard-Kelly K; Ngianga K; Thorne K; Asher C; Peveler RC; McCarthy J; Holt RIG
    Diabetes Obes Metab; 2021 Jun; 23(6):1262-1271. PubMed ID: 33528914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.
    Konwar M; Bose D; Jaiswal SK; Maurya MK; Ravi R
    Int J Clin Pract; 2022; 2022():1201977. PubMed ID: 35936066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide: a review of its use in the management of obesity.
    Scott LJ
    Drugs; 2015 May; 75(8):899-910. PubMed ID: 25985864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
    Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
    JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
    Gudbergsen H; Henriksen M; Wæhrens EE; Overgaard A; Bliddal H; Christensen R; Boesen MP; Knop FKK; Astrup A; Rasmussen MU; Bartholdy C; Daugaard C; Bartels EM; Ellegaard K; Heitmann BL; Kristensen LE
    BMJ Open; 2019 May; 9(5):e024065. PubMed ID: 31061017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
    Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.